These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 7407763

  • 1. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Valdivieso M, Moore EC, Burgess AM, Marti JR, Russ J, Plunkett W, Loo TL, Bodey GP, Freireich EJ.
    Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C, Donehower RC, Speyer JL, Klecker R, Chabner BA.
    J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
    [Abstract] [Full Text] [Related]

  • 4. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES, Gralla RJ, Kelsen DP, Houghton A, Golbey RB, Young CW.
    Cancer Treat Rep; 1980 Feb; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract] [Full Text] [Related]

  • 5. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA, Durrani FA, Rustum YM.
    Cancer Res; 1993 Apr 01; 53(7):1560-4. PubMed ID: 8453623
    [Abstract] [Full Text] [Related]

  • 6. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC, Markman M, Cleary S, Howell SB.
    Cancer Res; 1986 Jun 01; 46(6):3168-72. PubMed ID: 3698032
    [Abstract] [Full Text] [Related]

  • 7. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS, Gralla RJ, Kemeny NE.
    Cancer Treat Rep; 1980 Jun 01; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract] [Full Text] [Related]

  • 8. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES, Vale K, Williams LJ, Martin DS, Young CW.
    Cancer Res; 1983 May 01; 43(5):2324-9. PubMed ID: 6831457
    [Abstract] [Full Text] [Related]

  • 9. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
    Lankelma J, Penders PG, Leyva A, Kleeberg UR, Kenny JB, Bramwell V, McVie JG, Pinedo HM.
    Eur J Cancer Clin Oncol; 1981 Nov 01; 17(11):1199-204. PubMed ID: 7199467
    [No Abstract] [Full Text] [Related]

  • 10. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
    Markman M, Chan TC, Cleary S, Howell SB.
    Cancer Chemother Pharmacol; 1987 Nov 01; 19(1):80-3. PubMed ID: 3815730
    [Abstract] [Full Text] [Related]

  • 11. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
    Weiss GR, Ervin TJ, Meshad MW, Schade D, Branfman AR, Bruni RJ, Chadwick M, Kufe DW.
    Cancer Chemother Pharmacol; 1982 Nov 01; 8(3):301-4. PubMed ID: 7127661
    [Abstract] [Full Text] [Related]

  • 12. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET, O'Connell MJ, Kovach JS.
    Cancer; 1983 Aug 15; 52(4):615-8. PubMed ID: 6861099
    [Abstract] [Full Text] [Related]

  • 13. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA, Diggs CH, Scoltock M, Wiernik PH.
    Cancer Treat Rep; 1980 Aug 15; 64(2-3):339-42. PubMed ID: 7407767
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Kovach JS, Schutt AJ, Moertel CG, O'Connell MJ.
    Cancer Treat Rep; 1979 Aug 15; 63(11-12):1909-12. PubMed ID: 526923
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
    Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Casper ES, Young CW.
    Cancer Res; 1983 May 15; 43(5):2317-21. PubMed ID: 6187448
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of PALA.
    Gralla RJ, Casper ES, Natale RB, Yagoda A, Young CW.
    Cancer Treat Rep; 1980 May 15; 64(12):1301-5. PubMed ID: 7471120
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA, Capizzi RL, Muss HB, Smith S, Fernandes DJ, Homesley H, Loggie BW, Case L, Morris R, Russell GB, Richards F.
    Clin Cancer Res; 1996 Jul 15; 2(7):1107-14. PubMed ID: 9816275
    [Abstract] [Full Text] [Related]

  • 18. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.
    Stewart DJ, Leavens M, Friedman J, Benjamin RS, Moore EC, Bodey GP, Valdivieso M, Burgess MA, Wiseman C, Loo TL.
    Cancer Res; 1980 Sep 15; 40(9):3163-6. PubMed ID: 7427934
    [Abstract] [Full Text] [Related]

  • 19. PALA in advanced breast cancer. A phase II pilot study by the ECOG.
    Taylor SG, Davis TE, Falkson G, Keller AM.
    Am J Clin Oncol; 1982 Dec 15; 5(6):627-9. PubMed ID: 7165004
    [Abstract] [Full Text] [Related]

  • 20. N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
    Paridaens R, Mouridsen HT, Palshof T, Cocconi G, Van Oosterom A, Rotmensz N, Sylvester R, Heuson JC, Rozencweig M.
    Eur J Cancer Clin Oncol; 1982 Jan 15; 18(1):67-70. PubMed ID: 6211361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.